Repurposing Cationic Amphiphilic Antihistamines for Cancer Treatment

EBioMedicine

Volumn 9, Issue , 2016, Pages 130-139

  Ellegaard, Anne Marie ^a   Dehlendorff, Christian ^a   Vind, Anna C ^b   Anand, Atul ^a   Cederkvist, Luise ^a   Petersen, Nikolaj H T ^a,e   Nylandsted, Jesper ^a   Stenvang, Jan ^b   Mellemgaard, Anders ^c   Østerlind, Kell ^d   Friis, Søren ^a   Jäättelä, Marja ^a  

^a DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^d University of Copenhagen   (Denmark)

^e ORPHAZYME A S   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ASTEMIZOLE; CLEMASTINE; DESLORATADINE; EBASTINE; FEXOFENADINE; HISTAMINE H1 RECEPTOR ANTAGONIST; LORATADINE; TERFENADINE; ANTIHISTAMINIC AGENT; CATION;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER REGISTRY; CELL VIABILITY ASSAY; CONTROLLED STUDY; CYTOTOXICITY ASSAY; DRUG EFFICACY; DRUG REPOSITIONING; HUMAN; HUMAN CELL; LUNG ADENOCARCINOMA; LUNG CANCER CELL LINE; MULTIDRUG RESISTANCE; NON SMALL CELL LUNG CANCER; NONHUMAN; PHARMACOEPIDEMIOLOGY; PRIORITY JOURNAL; SQUAMOUS CELL LUNG CARCINOMA; WESTERN BLOTTING; A-549 CELL LINE; ADULT; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMISTRY; COHORT ANALYSIS; DENMARK; DRUG EFFECTS; DRUG RESISTANCE; LUNG NEOPLASMS; LYSOSOME; METABOLISM; MORTALITY; PROPORTIONAL HAZARDS MODEL; REGISTER; SURVIVAL RATE; TUMOR CELL LINE;

A549 CELLS; ADULT; APOPTOSIS; ASTEMIZOLE; BLOTTING, WESTERN; CARCINOMA, NON-SMALL-CELL LUNG; CATIONS; CELL LINE, TUMOR; COHORT STUDIES; DENMARK; DRUG REPOSITIONING; DRUG RESISTANCE, NEOPLASM; HISTAMINE ANTAGONISTS; HUMANS; LORATADINE; LUNG NEOPLASMS; LYSOSOMES; PROPORTIONAL HAZARDS MODELS; REGISTRIES; SURVIVAL RATE;

EID: 84991632895     PISSN: None     EISSN: 23523964     Source Type: Journal    
DOI: 10.1016/j.ebiom.2016.06.013     Document Type: Article

References (50)

1. Aits, S., Kricker, J., Liu, B., Ellegaard, A.M., Hämälistö, S., Tvingsholm, S., Corcelle-Termeau, E., Hogh, S., Farkas, T., Holm Jonassen, A., Gromova, I., Mortensen, M., Jäättelä, M., Sensitive detection of lysosomal membrane permeabilization by lysosomal galectin puncta assay. Autophagy 11 (2015), 1408–1424.
2. Baadsgaard, M., Quitzau, J., Danish registers on personal income and transfer payments. Scand. J. Public Health 39 (2011), 103–105.
3. Barcelo-Coblijn, G., Martin, M.L., De Almeida, R.F., Noguera-Salva, M.A., Marcilla-Etxenike, A., Guardiola-Serrano, F., Luth, A., Kleuser, B., Halver, J.E., Escriba, P.V., Sphingomyelin and sphingomyelin synthase (SMS) in the malignant transformation of glioma cells and in 2-hydroxyoleic acid therapy. Proc. Natl. Acad. Sci. U. S. A. 108 (2011), 19569–19574.
4. Carstensen, B., Plummer, M., Laara, E., Hills, M., Epi: A Package for Statistical Analysis in Epidemiology. R Package Version 1.1.71 [Online]. 2014 (Available: http://CRAN.R-project.org/package = Epi [Accessed December 15 2015]).
5. Chang, A., Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC. Lung Cancer 71 (2011), 3–10.
6. Charlson, M.E., Pompei, P., Ales, K.L., Mackenzie, C.R., A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J. Chronic Dis. 40 (1987), 373–383.
7. Del Cuvillo, A., Mullol, J., Bartra, J., Davila, I., Jauregui, I., Montoro, J., Sastre, J., Valero, A.L., Comparative pharmacology of the H1 antihistamines. J. Investig. Allergol. Clin. Immunol. 16:Suppl. 1 (2006), 3–12.
8. Edge, S.B., COMPTON, C.C., The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann. Surg. Oncol. 17 (2010), 1471–1474.
9. Ellegaard, A.M., Groth-Pedersen, L., Oorschot, V., Klumperman, J., Kirkegaard, T., Nylandsted, J., Jäättelä, M., Sunitinib and SU11652 inhibit acid sphingomyelinase, destabilize lysosomes, and inhibit multidrug resistance. Mol. Cancer Ther. 12 (2013), 2018–2030.
10. Fehrenbacher, N., Gyrd-Hansen, M., Poulsen, B., Felbor, U., Kallunki, T., Boes, M., Weber, E., Leist, M., Jäättelä, M., Sensitization to the lysosomal cell death pathway upon immortalization and transformation. Cancer Res. 64 (2004), 5301–5310.
11. Fehrenbacher, N., Bastholm, L., Kirkegaard-Sørensen, T., Rafn, B., Bottzauw, T., Nielsen, C., Weber, E., Shirasawa, S., Kallunki, T., Jäättelä, M., Sensitization to the lysosomal cell death pathway by oncogene-induced down-regulation of lysosome-associated membrane proteins 1 and 2. Cancer Res. 68 (2008), 6623–6633.
12. Fulda, S., Therapeutic exploitation of necroptosis for cancer therapy. Semin. Cell Dev. Biol. 35 (2014), 51–56.
13. Gjerstorff, M.L., The Danish Cancer Registry. Scand. J. Public Health 39 (2011), 42–45.
14. Gottesman, M.M., Fojo, T., Bates, S.E., Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev. Cancer 2 (2002), 48–58.
15. Groth-Pedersen, L., Jäättelä, M., Combating apoptosis and multidrug resistant cancers by targeting lysosomes. Cancer Lett. 332 (2013), 265–274.
16. Hanahan, D., Weinberg, R.A., Hallmarks of cancer: the next generation. Cell 144 (2011), 646–674.
17. Hansen, S.N., Westergaard, D., Thomsen, M.B., Vistesen, M., Do, K.N., Fogh, L., Belling, K.C., Wang, J., Yang, H., Gupta, R., Ditzel, H.J., Moreira, J., Brunner, N., Stenvang, J., Schrohl, A.S., Acquisition of docetaxel resistance in breast cancer cells reveals upregulation of ABCB1 expression as a key mediator of resistance accompanied by discrete upregulation of other specific genes and pathways. Tumour Biol. 36 (2015), 4327–4338.
18. Helweg-Larsen, K., The Danish register of causes of death. Scand. J. Public Health 39 (2011), 26–29.
19. Heykants, J., Van Peer, A., Woestenborghs, R., Jageneau, A., Vanden Bussche, G., Steady-state kinetics of astemizole in man. Drug Dev. Res. 8 (1986), 71–78.
20. Hilbert, J., Radwanski, E., Weglein, R., Luc, V., Perentesis, G., Symchowicz, S., Zampaglione, N., Pharmacokinetics and dose proportionality of loratadine. J. Clin. Pharmacol. 27 (1987), 694–698.
21. Jaffrezou, J.P., Chen, G., Duran, G.E., Muller, C., Bordier, C., Laurent, G., Sikic, B.I., Levade, T., Inhibition of lysosomal acid sphingomyelinase by agents which reverse multidrug resistance. Biochim. Biophys. Acta 1266 (1995), 1–8.
22. Jahchan, N.S., Dudley, J.T., Mazur, P.K., Flores, N., Yang, D., Palmerton, A., Zmoos, A.F., Vaka, D., Tran, K.Q., Zhou, M., Krasinska, K., Riess, J.W., Neal, J.W., Khatri, P., Park, K.S., Butte, A.J., Sage, J., A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung cancer and other neuroendocrine tumors. Cancer Discov. 3 (2013), 1364–1377.
23. Jensen, V.M., Rasmussen, A.W., Danish education registers. Scand. J. Public Health 39 (2011), 91–94.
24. Kallunki, T., Olsen, O.D., Jäättelä, M., Cancer-associated lysosomal changes: friends or foes?. Oncogene 32 (2013), 1995–2004.
25. Kildemoes, H.W., Sorensen, H.T., Hallas, J., The Danish National Prescription Registry. Scand. J. Public Health 39 (2011), 38–41.
26. Kolzer, M., Werth, N., Sandhoff, K., Interactions of acid sphingomyelinase and lipid bilayers in the presence of the tricyclic antidepressant desipramine. FEBS Lett. 559 (2004), 96–98.
27. Kornhuber, J., Tripal, P., Reichel, M., Terfloth, L., Bleich, S., Wiltfang, J., Gulbins, E., Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model. J. Med. Chem. 51 (2008), 219–237.
28. Kornhuber, J., Tripal, P., Reichel, M., Muhle, C., Rhein, C., Muehlbacher, M., Groemer, T.W., Gulbins, E., Functional inhibitors of acid sphingomyelinase (FIASMAs): a novel pharmacological group of drugs with broad clinical applications. Cell. Physiol. Biochem. 26 (2010), 9–20.
29. Leeson, G.A., Chan, K.Y., Knapp, W.C., Biedenbach, S.A., Wright, G.J., Okerholm, R.A., Metabolic disposition of terfenadine in laboratory animals. Arzneimittelforschung 32 (1982), 1173–1178.
30. Michiels, M., Van Peer, A., Woestenborghs, R., Heykants, J., Pharmacokinetics and tissue distribution of astemizole in the dog. Drug Dev. Res. 8 (1986), 53–62.
31. Molimard, M., Diquet, B., Benedetti, M.S., Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans. Fundam. Clin. Pharmacol. 18 (2004), 399–411.
32. NCI, NCI-60 cancer screening data [online]. National Cancer Institute, Developmental Therapeutic Program, 2015 (Available: https://dtp.cancer.gov/dtpstandard/cancerscreeningdata/index.jsp [Accessed November 1 2015]).
33. Ostenfeld, M.S., Høyer-Hansen, M., Bastholm, L., Fehrenbacher, N., Olsen, O.D., Groth-Pedersen, L., Puustinen, P., Kirkegaard-Sorensen, T., Nylandsted, J., Farkas, T., Jäättelä, M., Anti-cancer agent siramesine is a lysosomotropic detergent that induces cytoprotective autophagosome accumulation. Autophagy 4 (2008), 487–499.
34. Perera, R.M., Stoykova, S., Nicolay, B.N., Ross, K.N., Fitamant, J., Boukhali, M., Lengrand, J., Deshpande, V., Selig, M.K., Ferrone, C.R., Settleman, J., Stephanopoulos, G., Dyson, N.J., Zoncu, R., Ramaswamy, S., Haas, W., Bardeesy, N., Transcriptional control of autophagy-lysosome function drives pancreatic cancer metabolism. Nature 524 (2015), 361–365.
35. Petersen, N.H., Olsen, O.D., Groth-Pedersen, L., Ellegaard, A.M., Bilgin, M., Redmer, S., Ostenfeld, M.S., Ulanet, D., Dovmark, T.H., Lonborg, A., Vindelov, S.D., Hanahan, D., Arenz, C., Ejsing, C.S., Kirkegaard, T., Rohde, M., Nylandsted, J., Jäättelä, M., Transformation-associated changes in sphingolipid metabolism sensitize cells to lysosomal cell death induced by inhibitors of acid sphingomyelinase. Cancer Cell 24 (2013), 379–393.
36. Schmidt, M., Pedersen, L., Sorensen, H.T., The Danish Civil Registration System as a tool in epidemiology. Eur. J. Epidemiol. 29 (2014), 541–549.
37. Schmidt, M., Schmidt, S.A., Sandegaard, J.L., Ehrenstein, V., Pedersen, L., Sorensen, H.T., The Danish National Patient Registry: a review of content, data quality, and research potential. Clin. Epidemiol. 7 (2015), 449–490.
38. Schran, H.F., Petryk, L., Chang, C.T., O'Connor, R., Gelbert, M.B., The pharmacokinetics and bioavailability of clemastine and phenylpropanolamine in single-component and combination formulations. J. Clin. Pharmacol. 36 (1996), 911–922.
39. Schwab, D., Fischer, H., Tabatabaei, A., Poli, S., Huwyler, J., Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery. J. Med. Chem. 46 (2003), 1716–1725.
40. Shchors, K., Massaras, A., Hanahan, D., Dual targeting of the autophagic regulatory circuitry in gliomas with repurposed drugs elicits cell-lethal autophagy and therapeutic benefit. Cancer Cell 28 (2015), 456–471.
41. Siegel, R.L., Miller, K.D., Jemal, A., Cancer statistics, 2015. CA Cancer J. Clin. 65 (2015), 5–29.
42. Storm, H.H., Michelsen, E.V., Clemmensen, I.H., Pihl, J., The Danish Cancer Registry–history, content, quality and use. Dan. Med. Bull. 44 (1997), 535–539.
43. Sukhai, M.A., Prabha, S., Hurren, R., Rutledge, A.C., Lee, A.Y., Sriskanthadevan, S., Sun, H., Wang, X., Skrtic, M., Seneviratne, A., Cusimano, M., Jhas, B., Gronda, M., Maclean, N., Cho, E.E., Spagnuolo, P.A., Sharmeen, S., Gebbia, M., Urbanus, M., Eppert, K., Dissanayake, D., Jonet, A., Dassonville-Klimpt, A., Li, X., Datti, A., Ohashi, P.S., Wrana, J., Rogers, I., Sonnet, P., Ellis, W.Y., Corey, S.J., Eaves, C., Minden, M.D., Wang, J.C., Dick, J.E., Nislow, C., Giaever, G., Schimmer, A.D., Lysosomal disruption preferentially targets acute myeloid leukemia cells and progenitors. J. Clin. Invest. 123 (2013), 315–328.
44. Sundhedsdatastyrelsen, Medstat.dk [Online]. The Danish Health Data Authority (Sundhedsdatastyrelsen). 2016 (Available: http://www.medstat.dk/en [Accessed April 17 2016]).
45. Teres, S., Llado, V., Higuera, M., Barcelo-Coblijn, G., Martin, M.L., Noguera-Salva, M.A., Marcilla-Etxenike, A., Garcia-Verdugo, J.M., Soriano-Navarro, M., Saus, C., Gomez-Pinedo, U., Busquets, X., Escriba, P.V., 2-Hydroxyoleate, a nontoxic membrane binding anticancer drug, induces glioma cell differentiation and autophagy. Proc. Natl. Acad. Sci. U. S. A. 109 (2012), 8489–8494.
46. Therneau, T., A Package for Survival Analysis in S. Version 2.38 [Online]. 2014 (Available: http://CRAN.R-project.org/package = survival [Accessed December 15 2015]).
47. Thygesen, L.C., Daasnes, C., Thaulow, I., Bronnum-Hansen, H., Introduction to Danish (nationwide) registers on health and social issues: structure, access, legislation, and archiving. Scand. J. Public Health 39 (2011), 12–16.
48. Tillement, J.P., The advantages for an H1 antihistamine of a low volume of distribution. Allergy 55:Suppl. 60 (2000), 17–21.
49. Trapp, S., Rosania, G.R., Horobin, R.W., Kornhuber, J., Quantitative modeling of selective lysosomal targeting for drug design. Eur. Biophys. J. 37 (2008), 1317–1328.
50. WHO, WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC Classification and DDD Assignment [Online]. 2013, World Health Organization, Oslo, Norway (Available: http://www.whocc.no/atc_ddd_index/ [Accessed November 1 2015]).